RP-HPLC法测定注射用甲泼尼龙琥珀酸钠的含量

目的:建立反相HPLC法测定注射用甲泼尼龙琥珀酸钠的含量。方法:采用Agilent TC C18(2)(4.6 mm×250 mm,5μm)色谱柱,以水-四氢呋喃-甲酸(650∶350∶1)为流动相,流速:1.0 mL.min-1,检测波长:245 nm,柱温:30℃,进样体积:20μL。结果:琥珀酸甲泼尼龙在0.01～0.69 mg.mL-1浓度范围内呈良好线性关系(r=0.9999);平均回收率(n=9)为98.3%,RSD为0.3%。结论:本法简便、准确、重复性好,可用于注射用甲泼尼龙琥珀酸钠的含量测定。     

Methylprednisolone hemisuccinate and metabolites in urine from patients receiving high-dose corticosteroid therapy.

A reversed-phase high-performance liquid chromatographic (RP-HPLC) method for the measurement of methylprednisolone hemisuccinate (MPHS) and its metabolites methylprednisolone (MP), 20-alpha- (20a-HMP), and 20-beta-hydroxymethylprednisolone (20b-HMP) in urine is described. The metabolites were extracted from urine samples using Extrelut columns and eluted with ethylacetate. The mobile phase for RP-HPLC comprised methanol:citrate buffer:tetrahydrofuran (30:65:5, vol/vol/vol) with UV detection at 251 nm. Fractions were collected, pooled and the metabolites present were identified by gas chromatography-mass spectrometry and normal-phase HPLC (NP-HPLC). By RP-HPLC 30 +/- 7.3% (mean +/- 1 SD) of the dose was detected in the 0-24 h urine sample following a 1 g MPHS infusion to patients with rheumatoid arthritis; MPHS contributed 9.9 +/- 5.0%, MP 12.1 +/- 2.9%, 20a-HMP 7.8 +/- 2.2%, and 20b-HMP 1.0 +/- 0.3%, respectively. A further 1.0 +/- 0.9% of the administered dose was detected in urine collected 24-48 h postinfusion.     

Evaluation of the absorption,excretion and metabolism of [14 C] etoperidone in man

1. The absorption, excretion and metabolism of 2-{3-[4-(3-chlorophenyl)-1-piperazinyl]propyl}-4,5-diethyl-2,4-dihydro-3H-1,2,4 hydrochloride (etoperidone HCl) was investigated in six healthy men. Subjects were fasted overnight before receiving a single oral dose of a 100mg solution [14C] etoperidone HCl. 2. Plasma (0-48h), urine (0-120h) and faecal (0-120h) samples were collected. The terminal half-life of the total radioactivity from plasma was 21.7 ± 2.8?h with an apparent clearance of 1.01 ± 0.08 ml min-1. Recoveries of total radioactivity in urine and faeces were 78.8 ± 3.6% and 9.6 ± 4.1% of the dose, respectively. 3. Etoperidone and 21 metabolites were isolated and identified in the plasma, urine and faecal extracts. Unchanged etoperidone accounted for <0.01% of the dose in all excreta samples. Nine metabolites were identified in the plasma extracts and 21 urinary metabolites were identified. Seven faecal metabolites were identified. 4. Five proposed pathways were used to describe the formation of the metabolites: alkyl oxidation, piperazinyl oxidation, N -dealkylation, phenyl hydroxylation and conjugation. Alkyl oxidation of etoperidone resulted in the formation of 2-{3-[4-(3- chlorophenyl)-1-piperazinyl]propyl}-4-ethyl-2,4-dihydro-5-(1-hydroxyethyl)-3H-1 triazole-3-one. Piperazinyl oxidation of this metabolite leads to the formation of its N -oxide. N -dealkylation of the piperazinyl group led to the formation of 1-(3-chlorophenyl) piperazine and triazole propionic acid. Phenyl hydroxylation led to three important metabolites in the urine and faeces.     

The in vitro hepatic microsomal metabolism of 3,5-dimethyl-4-(phenylazo)-(1H)-pyrazole in rats

The in vitro hepatic microsomal metabolism of 3,5-dimethyl-4-(phenylazo)-(1H)-pyrazole (DMPAP) was studied using washed rat hepatic microsomal preparations fortified with NADPH. The substrate, DMPAP, and its potential metabolites, i.e. the corresponding reduction product, 3,5-dimethyl-4-amino-(1H)-pyrazole (DMAP), and the oxidation product, 3,5-dimethyl-4-(phenylazoxy)-(1H)-pyrazole (DMAPO), were synthesized and their structures elucidated by use of their spectral characteristics. DMPAP and its potential metabolites were then separated using a reverse phase HPLC system consisting of a C18 column and a mobile phase of acetonitrile:water (50:50) at a flow rate of 1 ml/min with UV detection at 254 nm. DMPAP was incubated with rat microsomal preparations, extracted into DCM in the presence of NaCl, and finally evaporated under a stream of nitrogen. The results from HPLC studies showed that DMPAP was metabolised to the corresponding reduction and oxidation products in the presence of NADPH.     

Evaluation of the absorption, excretion and metabolism of [14C] etoperidone in man.

1. The absorption, excretion and metabolism of 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-4,5-diethyl-2,4-dihydro-3H-1,2,4- triazole-3-one hydrochloride (etoperidone HCl) was investigated in six healthy men. Subjects were tasted overnight before receiving a single oral dose of a 100 mg solution [14C] etoperidone HCl. 2. Plasma (0-48 h), urine (0-120 h) and faecal (0-120 h) samples were collected. The terminal half-life of the total radioactivity from plasma was 21.7 +/- 2.8h with an apparent clearance of 1.01 +/- 0.08 ml min(-1). Recoveries of total radioactivity in urine and faeces were 78.8 +/- 3.6% and 9.6 +/- 4.1% of the dose, respectively. 3. Etoperidone and 21 metabolites were isolated and identified in the plasma, urine and faecal extracts. Unchanged etoperidone accounted for <0.01% of the dose in all excreta samples. Nine metabolites were identified in the plasma extracts and 21 urinary metabolites were identified. Seven faecal metabolites were identified. 4. Five proposed pathways were used to describe the formation of the metabolites: alkyl oxidation, piperazinyl oxidation, N-dealkylation, phenyl hydroxylation and conjugation. Alkyl oxidation of etoperidone resulted in the formation of 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-4-ethyl-2,4-dihydro-5- (1-hydroxyethyl)-3H-1,2,4-triazole-3-one. Piperazinyl oxidation of this metabolite leads to the formation of its N-oxide. N-dealkylation of the piperazinyl group led to the formation of 1-(3-chlorophenyl) piperazine and triazole propionic acid. Phenyl hydroxylation led to three important metabolites in the urine and faeces.     

HPLC法测定豚鼠外淋巴液和血浆中甲泼尼龙的含量

目的建立豚鼠外耳淋巴液和血浆中甲泼尼龙含量的测定方法。方法应用HPLC法测定甲泼尼龙的含量。HPLC色谱条件为ZORBAX Eclipse XDB-C18色谱柱（250 mm×4.6 mm,5μm）,流动相为7.56 mmol·L^-1硫酸铵-乙腈（68：32,V/VV）,流速1.0 mL·min^-1,柱温20℃,紫外检测波长243 nm。结果本研究建立的HPLC法,用于测定豚鼠外淋巴液和血浆中甲泼尼龙含量时的线性范围分别为0.05～5.0 mg·L^-1（r=0.999 6）和0.10～5.0 mg·L^-1（r=0.999 5）。给药后2 h鼓阶外淋巴液中甲泼尼龙的质量浓度为（0.14±0.02）mg·L^-1,血浆质量浓度为（1.67±0.19）mg·L^-1。结论方法灵敏、准确,重现性好,可用于血浆和外淋巴液中甲泼尼龙的测定。     

Evaluation of essential parameters in the chromatographic determination of cyclosporin A and metabolites using a D-optimal design

The extensive use of routine monitoring of cyclosporin A (INN, ciclosporin) whole blood levels of patients undergoing such therapy has resulted in a wide variety of chromatographic conditions for analysing this drug. The aim of this study was to evaluate the importance of essential parameters in the chromatographic determination of cyclosporin A and its main metabolites, AM1, AM9 and AM4N. A D-optimal design was used to evaluate the effect of type and amount of organic modifier, temperature, flow rate, pH and gradient steepness. The optimal chromatographic conditions were determined by multi-linear regression. In the final chromatographic method separation of the compounds was carried out on a reversed phase C(8) column maintained at 80 degrees C. The mobile phase consisted of a linear gradient with two mobile phases containing acetonitrile and water. The flow rate was set at 0.8 ml/min. UV detection was carried out at 214 nm. Validation of the analytical method showed linearity over the range 25-1000 ng/ml (r>0.997). The detection limits of cyclosporin A, AM1, AM9 and AM4N were 1.3 pmol on column. The within-day and between-day relative standard deviations were <15% for cyclosporin A at all concentrations and for the metabolites at 250 and 1000 ng/ml, and <21% for the metabolites at limit of quantification (25 ng/ml).     

Identification of two main urinary metabolites of [14C]omeprazole in humans

The excretion and metabolism of [14C]omeprazole given orally as a suspension was studied in 10 healthy male subjects. An average of 79% of the dose was recovered in the urine in 96 hr, with most of the radioactivity (76% of dose) being eliminated in the first 24 hr. Pooled urine (0-2 hr) from five subjects, containing about 47% of the dose, was analyzed by reverse phase gradient elution LC with radioisotope detection. Omeprazole was completely metabolized to at least six metabolites. The two major metabolites were extensively purified by LC and their structures were determined by MS with derivatization and use of stable isotopes, 1H NMR, and comparison with synthetic references. They were formed by hydroxylation of a methyl group in the pyridine ring, followed by further oxidation of the alcohol to the corresponding carboxylic acid. Both metabolites retained the sulfoxide group of omeprazole, rendering them as unstable as the parent compound at pH less than 7. They accounted for approximately 28% (hydroxyomeprazole) and 23% (omeprazole acid) of the amount excreted in the 0-2-hr collection interval. Based on in vitro studies with the synthetic metabolites in isolated gastric glands, it is unlikely that M1 and M2 will contribute to the pharmacological effect of omeprazole in humans.     

Metabolites of [3-13C]1,2-dibromo-3-chloropropane in male rats studied by 13C and 1H-13C correlated two-dimensional NMR spectroscopy

Metabolism of 1,2-dibromo-3-chloropropane (DBCP) was examined by direct 13C and 1H-13C correlated two-dimensional NMR spectroscopy of bile and urine of male albino rats treated intraperitoneally with [3-13C]DBCP at 81 mg/kg. The 3-13C label was introduced at 99% enrichment by coupling [13C]paraformaldehyde with vinyllithium to give [1-13C]allyl alcohol which was converted to allyl chloride with carbon tetrachloride/triphenylphosphine and then brominated. Fifteen 13C NMR signals were observed for biliary metabolites and twelve for urinary metabolites. Nine of the biliary metabolite 13C NMR signals were very similar or identical to those for nine urinary metabolites. The DBCP-derived moieties of five metabolites were identified by comparison of their 13C NMR chemical shifts, 13C multiplicities [obtained via the distortionless enhancement by polarization transfer (DEPT) pulse sequence], and chemical shifts of the directly-attached protons (obtained via two-dimensional NMR) with those of authentic standards. They were E- and Z-RSCH2CH = 13CHCl, RSCH2CHOH13CH2Cl, RSCH2CHOH13CH2OH and RS13CH2CHOHCH2OH, where R is probably glutathionyl in bile and N-acetylcysteinyl in urine. The mechanism proposed for formation of both the E- and Z-isomers of RSCH2CH = 13CHCl involves radical-initiated dehydrobromination followed by reaction of the intermediate allylic bromides with glutathione (GSH). The RSCH2CHOHCH2Cl conjugate may arise from direct GSH conjugation and hydrolysis of the secondary bromine via a thiiranium ion intermediate. The proposed origin of the RSCH2CHOHCH2OH conjugate labeled at either carbon-1 or carbon-3 is oxidation of DBCP at the bromomethyl or chloromethyl substituent, respectively, followed by two spontaneous dehydrohalogenations to give the highly reactive 2-bromopropenal, and addition of GSH followed by reduction of the aldehyde functionality. An alternative mechanism for the formation of the RSCH2CHOHCH2Cl and RSCH2CHOHCH2OH derivatives involves carbon-2 oxidation to give 1-bromo-3-chloroacetone followed by reaction with GSH and reduction of the ketone functionality with or without hydrolysis of the chloro substituent. 2-Bromopropenal, 1-bromo-3-chloroacetone, or GSH conjugates derived from these intermediates may be involved in the male reproductive toxicity, nephrotoxicity and genotoxicity of DBCP.     

The analysis of SK&F 94120, a novel inotropic agent, and its four metabolites by isolation on C18 AASP cassettes followed by high-performance liquid chromatography

A selective and specific assay for SK&F 94120 [5-(4-acetamidophenyl)pyrazin-2(1H)-one] and its four metabolites in plasma has been developed. The method incorporates a single liquid-solid extraction step using C18 Analytichem Automated Sample Processor (AASP) cassettes. This is followed by successive elutions of the solid phase with two mobile phases of increasing acetonitrile content, by an AASP liquid chromatography module. A mobile phase containing 10% acetonitrile elutes a glucuronide metabolite from the cartridge which is then chromatographed and quantified intact. A second mobile phase, containing 20% acetonitrile, is then used to elute the unchanged drug and the three other metabolites from the same cartridge. The assay shows good accuracy and precision (less than 10% for all analytes) and is able to determine SK&F 94120 and its metabolites in plasma at concentrations between 0.05 and 1.00 mg l(-1).     

Metabolism of 1-[14C]nitropyrene in isolated perfused rat livers

1-Nitropyrene (1-NP), a constituent of diesel exhaust, is carcinogenic to rats and is a bacterial and mammalian mutagen. Biliary and fecal excretion of 1-NP metabolites are the major routes of excretion in rats, suggesting that hepatic metabolism plays a dominant role in determining the biological fate of 1-NP. The purpose of this investigation was to quantitate 1-[14C]NP metabolites formed in isolated perfused rat livers and excreted in bile from rats. Perfused rat livers displayed a capacity for oxidation, reduction, acetylation, and conjugation of 1-NP (or its metabolites). Reduction of 1-NP followed by N-acetylation was the major metabolic pathway observed in the perfused livers. Acetylaminopyrene (AAP) was the major metabolite detected, with total quantities (150 nmol) accounting for about 60% of the total 1-[14C]NP dose (258 nmol) added to the perfusate. Considerably smaller quantities of aminopyrene and hydroxynitropyrenes were also detected. Livers perfused with 1-[14C]NP excreted about 36 nmol equivalents of 1-[14C]NP (12% of the total 1-NP dose) in bile after 60 min. Some of the biliary metabolites were tentatively identified as metabolites of the mercapturic acid pathway. The spectrum of biliary metabolites was qualitatively identical to that seen in bile from intact rats. Quantities of 14C covalently bound to hepatic macromolecules from perfused livers were 0.4 nmol 1-NP eq/g liver. The data from this study indicate that the liver may be an important site for metabolism of 1-NP.     

Analysis of [14C]-saterinone and its metabolites in dog plasma, urine and bile by high-performance liquid chromatography with radioactivity and fluorescence detection and by mass spectrometry.

An HPLC method was developed for the direct on-line radioactivity determination of [14C]-saterinone and its metabolites in biological canine fluids after intravenous and intraduodenal administration. After direct injection of 200 microliters of sample, the metabolites were separated on a semi-preparative reverse-phase column. The metabolites were identified by HPLC reference standards, enzymatic hydrolysis and mass spectrometry. Besides a small amount of unchanged saterinone, six metabolites could be detected, both in bile and urine. The main fraction (about 80-90% of the sum of detected metabolites) contained the phase II metabolites of saterinone, the sulphate and glucuronide. Ring hydroxylated saterinone and three metabolites that were not identified made up about 1-4% each. In plasma, only the major compounds could be detected because of the lower absolute concentrations. The metabolic pathway of saterinone in dogs was elucidated and compared with other species. Results from previous studies concerning a first-pass metabolism could be confirmed.     

In vivo formation of codeinone and morphinone from codeine. Isolation and identification from guinea pig bile.

Codeinone (CO) and morphinone (MO) were isolated and identified in the bile of guinea pigs given sc injections of codeine. Authentic CO was synthesized and characterized by the NMR and mass spectra of its 2-mercaptoethanol (ME) adduct. This material was then used as the standard to identify the CO-ME adduct in the bile of codeine-treated animals. The MO-ME adduct was also identified in the bile with authentic materials prepared earlier. The results of our investigations indicated that 10.5 and 2.7% dose of CO and MO, respectively, were produced for 6 hr after the codeine was given. The metabolites were separated by preparative HPLC on a reverse phase column packed with C18 gel using a 10 mM sodium phosphate buffer, pH 6.8/CH3CN, 1:1 (v/v) as an eluate. For the further purification of metabolites, we used another reverse phase column with the same mobile phase. A structural elucidation of the ME adduct of metabolites was then performed by fast atom bombardment mass spectroscopy and 400 MHz fourier transform-NMR spectrometric analysis, and identified as (8S)-(2-hydroxyethylthio)dihydrocodeinone and (8S)-(2-hydroxyethylthio)dihydromorphinone, respectively.     

LC-ESI-MSD fast determination of residual mitomycin C in hen aqueous humour after corneal refractive surgery

A simple, fast and reliable method has been developed for the assay of traces of mitomycin C (MMC) in hen aqueous humour samples. The determination was carried out by high-performance liquid chromatography with electrospray ionization mass spectrometric detection. In isocratic elution analysis, the mobile phase was a mixture of water-acetonitrile (78:22, v/v) and the chromatographic column was C(18) at 35 degrees C. The method has been validated over a range from 0.1 to 250 microg L(-1) in hen aqueous humour with correlation coefficients higher than 0.999. Limit of detection and limit of quantification for MMC based in signal to noise ratio of 3 and 10, respectively, were 20 and 71 ng L(-1). The developed method allows the analysis of MMC in hen aqueous humour samples obtained at different times and conditions in order to evaluate and compare the efficacy of the drug administration.     

RP-HPLC法测定尿液中非蛋白氮代谢产物的含量

目的建立RP-HPLC法同时测定尿液中尿素、肌酸、肌酐、尿酸和马尿酸5种非蛋白氮代谢产物。方法色谱柱为Century C18柱(200 mm×4.6 mm,5μm),以乙腈-20 mmol.L-1乙酸铵缓冲液(pH 6.8)为流动相,进行梯度洗脱,检测波长为220 nm。结果肌酸、肌酐、尿酸和马尿酸的质量浓度在2~100 mg.L-1内、尿素的质量浓度在100~1 000 mg.L-1内线性关系良好,方法平均回收率为97.6%~105.7%,RSD均小于4.2%。结论该法灵敏、准确,适用于临床尿液中非蛋白氮代谢产物的检测。     

Simultaneous analysis of dextran-methylprednisolone succinate, methylprednisolone succinate, and methylprednisolone by size-exclusion chromatography

An analytical HPLC method is reported for simultaneous measurement of low (1.0-100 microg ml(-1)) concentrations of dextran-methylprednisolone succinate (DEX-MPS) and its degradation products methylprednisolone hemisuccinate (MPS) and methylprednisolone (MP). The analytes were detected at 250 nm after resolution using a size exclusion column with a mobile phase of KH2PO4 (10 mM): acetonitrile (3:1) and a flow rate of 1 ml min(-1). The resolution of MP and MPS peaks was substantially affected by the pH of the mobile phase; while MP and MPS co-eluted at pH 3.4, they were baseline-resolved at pH > or = 5. Linear relationships (r > or = 0.997) were found between the detector response and the concentrations of the analytes (1.0-100 microg ml(-1) for MP and MPS and 2.5-100 microg ml(-1) for DEX-MPS). Intra- and inter-run error (< 13%) and precision (CV of < or = 6%) data indicated that the assay could accurately and precisely quantitate all three components in the examined concentration range. The application of the assay to determination of degree of substitution, purity, and stability of DEX-MPS was also demonstrated.     

Studies related to the metabolism of anabolic steroids in the horse: the phase I and phase II biotransformation of 19-nortestosterone in the equine castrate

The metabolism of 19-nor[4-14C]testosterone has been studied in the equine castrate. Following XAD-2 extraction of aliquots of the 0-24 h urine samples, the glucuronic acid and sulphate conjugates were separated by Sephadex LH-20 column chromatography. After hydrolysis of the conjugates, the neutral phase I metabolites of 19-nortestosterone were extracted, purified and identified by g.l.c.-mass spectrometry. In phase I metabolism stereospecificity was observed in the reduction of the A-ring with the formation of the 5 alpha, 3 beta-isomers of estranediol. Epimerization at C-17 and hydroxylation at C-16 were the other major pathways. In phase II metabolism the C-17 alpha steroid epimers were predominantly conjugated with glucuronic acid and the C-17 beta epimers with sulphuric acid. One animal showed a slight variation in metabolism with a tendency towards the formation of polar metabolites.     

Direct detection of antipyrine metabolites in rat urine by (13)C labeling and NMR spectroscopy.

Antipyrine is a useful probe to evaluate variation of in vivo activities of oxidative hepatic drug-metabolizing enzymes. Here we describe a new approach using (13)C labeling and NMR spectroscopy for the direct and simultaneous detection of all phase I and phase II metabolites of antipyrine in rat urine. [C-methyl-(13)C]Antipyrine was synthesized and administered orally to rats (100 mg/kg), and the 0- to 24-h postdose urine was analyzed by 100-MHz (13)C NMR spectroscopy under the conditions of distortionless enhancement by polarization transfer without any pretreatments such as deconjugation, chromatographic separation, and solvent extraction. Consequently, all the major metabolites in urine were successfully detected with favorable signal-to-noise ratios in the limited acquisition time (30 min). The assignments of the resonances were performed by enzymic modification and spiking authentic samples. The reproducibility of the NMR detection was sufficient for the quantitative evaluation of the metabolic profile. Effects of 3-methylcholanthrene on antipyrine metabolism were examined by this approach to evaluate variation of in vivo phase I and phase II metabolism of antipyrine in rats. The present approach is useful and practical to evaluate variation of in vivo activities of conjugation enzymes as well as oxidation enzymes responsible for the formation of antipyrine metabolites in rats. This direct approach would enhance the value of the antipyrine test because of the simplicity and convenience.     

HPLC法测定维生素C注射液的含量

目的：建立用HPLC测定维生素C注射液含量的方法。方法采用 Thermo Scientific HYPERSIL ODS C18（250mm ×4．6mm,5μm）色谱柱,流动相：A相：0．1％磷酸－水,B相：甲醇;流速1mL? min －1;检测波长245nm;柱温25℃。结果线性回归方程为A＝3879545X＋9213,R2＝0．9999,线性范围0．0618～0．5562μg,平均回收率为99．38％（ RSD 0．47％）。结论该方法操作简单,快速准确且重复性好,可用于维生素 C注射液的含量测定。     

Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers.

PURPOSE: The compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in 5% dextrose injection and 0.9% sodium chloride injection was studied. METHODS: Test solutions of ondansetron hydrochloride 0.16 mg/mL and methylprednisolone sodium succinate 2.4 mg/mL were prepared in triplicate and tested in duplicate. Total volumes of 4 and 2 mL of ondansetron hydrochloride solution and methylprednisolone sodium succinate solution, respectively, were added to 50-mL multilayer polyolefin bags containing 5% dextrose injection or 0.9% sodium chloride injection. Bags were stored for 24 hours at 20-25 degrees C and for 48 hours at 4-8 degrees C. Chemical compatibility was measured with high-performance liquid chromatography, and physical compatibility was determined visually. RESULTS: Ondansetron hydrochloride was stable for up to 24 hours at 20-25 degrees C and up to 48 hours at 4-8 degrees C. Methylprednisolone sodium succinate was stable for up to 48 hours at 4-8 degrees C. When stored at 20-25 degrees C, methylprednisolone sodium succinate was stable for up to 7 hours in 5% dextrose injection and up to 24 hours in 0.9% sodium chloride injection. Compatibility data for solutions containing ondansetron hydrochloride plus methylprednisolone sodium succinate revealed that each drug was stable for up to 24 hours at 20-25 degrees C and up to 48 hours at 4-8 degrees C. CONCLUSION: Ondansetron 0.16 mg/mL (as the hydrochloride) and methylprednisolone 2.4 mg/mL (as the sodium succinate) mixed in 50-mL multilayer polyolefin bags were stable in both 5% dextrose injection and 0.9% sodium chloride injection for up to 24 hours at 20-25 degrees C and up to 48 hours at 4-8 degrees C.